Source: Health Products Regulatory Authority (IE) Revision Year: 2025 Publisher: Substipharm, 24 rue Erlanger, 75016 Paris, France
Iverscab 3 mg tablets.
| Pharmaceutical Form |
|---|
|
Tablet. The tablets are round, white or almost white, flat chamfered with a diameter of 5.5 mm and thickness of 2.1 mm. |
1 tablet contains 3 mg of ivermectin.
For the full list of excipients, see section 6.1.
| Active Ingredient |
|---|
|
Ivermectin is a member of the avermectin class and has high affinity with glutamate-gated chloride channels present in invertebrate nerve and muscle cells. Its binding to these channels promotes an increase in membrane permeability to chloride ions, leading to hyperpolarization of the neural or muscle cell. This results in neuromuscular paralysis and may lead to the death of certain parasites. |
| List of Excipients |
|---|
|
Cellulose, microcrystalline (E460) |
4, 8, 10, 12, 16 or 20 tablets in Polyamide/Aluminium/PVC/Aluminium blisters.
Not all pack sizes may be marketed.
Substipharm, 24 rue Erlanger, 75016 Paris, France
PA1677/008/001
Date of first authorisation: 12th September 2025
Date of last renewal: 26th of February 2026
| Drug | Countries | |
|---|---|---|
| IVERSCAB | Ireland |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.